A schematic overview of this therapeutic concept is provided in Figure 2, which illustrates the workflow of 211At-labeled LAT1-targeted therapy, including target identification, vector design (antibody/peptide/small molecule), radiolabeling, tumor accumulation, and the induction of clustered DNA double-strand breaks by short-range, high-LET α-particles. This evidence concerns the gene SLC7A5 and neoplasm.